Climb Bio Inc. Company Profile
NASDAQ: CLYMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Climb Bio at a glance
Climb Bio Inc. (NASDAQ: CLYM) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Wellesley Hills, MA. Climb Bio is led by Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc and employs about 28 people. The company's shares have traded publicly since 2021.
At a market capitalization of $615.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001768446, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Climb Bio do?
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Climb Bio Inc.
- Ticker
- NASDAQ: CLYM
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
- Employees
- 28
- Headquarters
- 20 William Street, Wellesley Hills, MA, United States
- Phone
- 866 857 2596
- Website
- climbbio.com
- IPO year
- 2021
- Market cap
- $615.14M
- SEC CIK
- 0001768446
- Latest annual report
- 10-K · Mar 5, 2026
Companies similar to Climb Bio
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SGMTSagimet Biosciences Inc. Series A | 8.92 | +0.45% | $632.51M | vs CLYM |
| IRWDIronwood Pharmaceuticals Inc. Class A | 3.87 | +3.20% | $639.48M | vs CLYM |
| ABUSArbutus Biopharma Corporation | 4.18 | -2.56% | $640.69M | vs CLYM |
| ZVRAZevra Therapeutics Inc. | 11.00 | -0.72% | $653.22M | vs CLYM |
| CRMDCorMedix Inc. | 7.32 | +0.55% | $570.55M | vs CLYM |
| FTHFaeth Therapeutics Inc. | 25.61 | +2.77% | $661.77M | vs CLYM |
| STTKShattuck Labs Inc. | 5.66 | +0.09% | $568.06M | vs CLYM |
| MNPRMonopar Therapeutics Inc. | 83.98 | +0.24% | $563.69M | vs CLYM |